COVID-19 Critical Intelligence Unit

## **Daily evidence digest**

7 September 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

# SARS-CoV-2 vaccination in immune-mediated inflammatory diseases, anakinra for early treatment, anti-SARS-CoV-2 seroprevalence in the US

#### Peer reviewed journals featured:

- A systematic review on SARS-CoV-2 vaccination in immune-mediated inflammatory diseases here
- A randomised controlled trial of anakinra for early treatment of COVID-19 here
- Narrative reviews on:
  - Major registries of people with cancer diagnosed with COVID-19 <u>here</u>
  - Embedding behaviours that protect against COVID-19 transmission in the UK here
- Observational studies on:
  - o Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence here
  - Emergency Department encounters among youth with suicidal thoughts or behaviours in Northern California <u>here</u>
  - o Antibody response to the Pfizer vaccine in patients undergoing haemodialysis here
  - Ascorbic acid as adjunctive therapy in critically ill COVID-19 patients here
- A modelling study on outcomes associated with social distancing policies in St Louis <u>here</u>
- Commentary on:
  - Emotional supportive care for first-degree relatives of deceased COVID-19 people <u>here</u>
  - A spike in stillbirths during COVID-19 in India here

#### Letters and correspondence discussed:

- The rate of recurrent Guillain-Barré syndrome after Pfizer vaccine here
- Association between exposure characteristics and the risk for COVID-19 infection among healthcare workers, with and without vaccination <u>here</u>
- SARS-CoV-2 antibody responses by age among recipients of the Pfizer and Moderna vaccine here

### Pre-peer review articles featured:

- COVID-19 vaccine effectiveness during a Delta variant surge in Oregon <u>here</u>
- Viral loads of Delta variant breakthrough infections following Pfizer vaccination and booster <u>here</u>
- Monitoring populations at increased risk for SARS-CoV-2 infection in the UK <u>here</u>
- Mitigating the fourth wave of COVID-19 in Ontario, Canada here
- The risk of hospitalisation for cases of the Delta and Alpha variants in Norway here



#### Guidance and reports

- The World Health Organization published guidance on COVID-19 immunisation for refugees and migrants <u>here</u>
- The Therapeutic Goods Administration (TGA) issued provisional approval of the Moderna vaccine for people aged 12-17 years <u>here</u>
- A Cochrane systematic review on SARS-CoV-2-neutralising monoclonal antibodies for COVID-19 treatment <u>here</u>
- The American Society of Haematology updated its guidelines on the use of anticoagulation for thromboprophylaxis in COVID-19 patients <u>here</u>
- Public Health England published an update on SARS-CoV-2 variants of concern and variants under investigation <u>here</u>

#### News and blogs

- The UK's Joint Committee on Vaccination and Immunisation does not recommend universal vaccination for children aged 12-15 years old <u>here</u>
- An open letter to the unvaccinated <u>here</u>
- India's DNA (ZyCoV-D) COVID-19 vaccine is a world-first <u>here</u>
- Calming the cytokine storm in COVID-19 here

<u>Click here</u> to subscribe to the daily evidence digest.

#### Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on <u>COVID-19 transmission</u>, SARS-CoV-2 <u>vaccines</u>, and <u>variants</u> of concern, <u>post-acute sequelae of</u> <u>COVID-19 (PASC)</u>, <u>surgery and COVID-19</u>, and <u>rapid testing</u>.



The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.